These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34729382)

  • 1. Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics.
    Charitidis FT; Adabi E; Thalheimer FB; Clarke C; Buchholz CJ
    Mol Ther Methods Clin Dev; 2021 Dec; 23():359-369. PubMed ID: 34729382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR Gene Delivery by T-cell Targeted Lentiviral Vectors is Enhanced by Rapamycin Induced Reduction of Antiviral Mechanisms.
    Charitidis FT; Adabi E; Ho N; Braun AH; Tierney C; Strasser L; Thalheimer FB; Childs L; Bones J; Clarke C; Buchholz CJ
    Adv Sci (Weinh); 2023 Dec; 10(35):e2302992. PubMed ID: 37904721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors.
    Jamali A; Kapitza L; Schaser T; Johnston ICD; Buchholz CJ; Hartmann J
    Mol Ther Methods Clin Dev; 2019 Jun; 13():371-379. PubMed ID: 30997367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturing.
    Luostarinen A; Kailaanmäki A; Turkki V; Köylijärvi M; Käyhty P; Leinonen H; Albers-Skirdenko V; Lipponen E; Ylä-Herttuala S; Kaartinen T; Lesch HP; Kekarainen T
    Cytotherapy; 2024 Sep; 26(9):1084-1094. PubMed ID: 38661611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Generation of CAR T Cells Selectively in Human CD4
    Agarwal S; Hanauer JDS; Frank AM; Riechert V; Thalheimer FB; Buchholz CJ
    Mol Ther; 2020 Aug; 28(8):1783-1794. PubMed ID: 32485137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes.
    Kapitza L; Ho N; Kerzel T; Frank AM; Thalheimer FB; Jamali A; Schaser T; Buchholz CJ; Hartmann J
    Front Immunol; 2023; 14():1183698. PubMed ID: 37646032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells.
    Cordes N; Kolbe C; Lock D; Holzer T; Althoff D; Schäfer D; Blaeschke F; Kotter B; Karitzky S; Rossig C; Cathomen T; Feuchtinger T; Bürger I; Assenmacher M; Schaser T; Kaiser AD
    Mol Ther Methods Clin Dev; 2021 Jun; 21():42-53. PubMed ID: 33768128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8.
    Michels A; Frank AM; Günther DM; Mataei M; Börner K; Grimm D; Hartmann J; Buchholz CJ
    Mol Ther Methods Clin Dev; 2021 Dec; 23():334-347. PubMed ID: 34729380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors.
    Chockley P; Patil SL; Gottschalk S
    Cytotherapy; 2021 Sep; 23(9):787-792. PubMed ID: 34119434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors.
    Frank AM; Braun AH; Scheib L; Agarwal S; Schneider IC; Fusil F; Perian S; Sahin U; Thalheimer FB; Verhoeyen E; Buchholz CJ
    Blood Adv; 2020 Nov; 4(22):5702-5715. PubMed ID: 33216892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib is a potent enhancer for CAR T cell generation by CD3-targeted lentiviral vectors.
    Braun AH; Frank AM; Ho N; Buchholz CJ
    Mol Ther Methods Clin Dev; 2023 Mar; 28():90-98. PubMed ID: 36620073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ho N; Agarwal S; Milani M; Cantore A; Buchholz CJ; Thalheimer FB
    Mol Ther Methods Clin Dev; 2022 Sep; 26():144-156. PubMed ID: 35795778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Agarwal S; Weidner T; Thalheimer FB; Buchholz CJ
    Oncoimmunology; 2019; 8(12):e1671761. PubMed ID: 31741773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression.
    Kimura T; Koya RC; Anselmi L; Sternini C; Wang HJ; Comin-Anduix B; Prins RM; Faure-Kumar E; Rozengurt N; Cui Y; Kasahara N; Stripecke R
    Mol Ther; 2007 Jul; 15(7):1390-9. PubMed ID: 17505480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus.
    Rive CM; Yung E; Dreolini L; Brown SD; May CG; Woodsworth DJ; Holt RA
    Mol Ther Methods Clin Dev; 2022 Sep; 26():4-14. PubMed ID: 35755944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from serum-supplemented monolayer to serum-free suspension lentiviral vector production for generation of chimeric antigen receptor T cells.
    Tirapelle MC; Oliveira Lomba AL; Silvestre RN; Mizukami A; Covas DT; Picanço-Castro V; Swiech K
    Cytotherapy; 2022 Aug; 24(8):850-860. PubMed ID: 35643755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.